Beneath these surface movements, a structural picture is clarifying. What is forming is not a collapse of the psychedelic therapeutics project — it is a compression. The regulatory, legislative, and enforcement systems are all tightening simultaneously, creating a narrowing gate through which the field must pass. This is historically significant: moments of maximum institutional resistance often precede the most durable advances, because they force the evidence base to become undeniable rather than merely promising. The binary catalysts are now named — COMPASS and ATAI Q3 2026 clinical data readouts will either reinforce or dissolve the current bearish sentiment. If those data are strong, the compression breaks in the direction of credibility. If they disappoint, a longer consolidation cycle becomes the dominant path. The highest trajectory genuinely available from here is not speed — it is depth. The field is being forced to build the kind of evidentiary foundation that regulators cannot refuse and courts cannot overturn. That is slow. It is also the only path that holds.
For the veterans waiting for ibogaine access, for the PTSD patients who have exhausted every approved option, for the families watching someone they love cycle through SSRIs and dissociation, today's signals carry a specific texture: another delay in a sequence of delays. The ketamine clinic enforcement actions will not feel like caution to the patient who found relief there and may now find their provider gone. What is genuinely possible for these people — and this must be named without flinching — depends on whether the evidentiary work happening right now in trials and clinics and peer-reviewed literature becomes so undeniable that the institutional gate cannot hold. That possibility is real. It is not guaranteed, and it is not close. But the research is not pausing. The human need is not diminishing. The thread between those two facts is still intact.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The medicine is older than the fear. The healing is older than the wound.
84%
Psilocybin and MDMA stay illegal under federal law through 2026
The U.S. government will not officially move psilocybin or MDMA to a less-restricted legal category before the end of 2026. This matters because it means people can't legally use these drugs for therapy anywhere in America, and companies can't sell them, no matter what state you live in.
→ Psilocybin and MDMA will remain federally illegal for therapy through 2026, blocking nationwide medical access.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
Neither psilocybin nor MDMA is rescheduled under the Controlled Substances Act before December 31, 2026.. DEA rescheduling requires agency concurrence and completion of a formal comment and review period—a process that takes 12–24 months minimum once initiated. No active rescheduling petition for either substance is at final-rule stage as of June 2026. DEA has signaled willingness to use procedural tool
81%
FDA rejects MDMA-assisted therapy application, requests more data
The FDA (the U.S. drug regulator) will not approve MDMA-assisted therapy for use as a medicine by the end of 2026. Instead, the FDA will send back a Complete Response Letter—official rejection asking the company to submit more clinical trial data. This matters because it delays MDMA therapy access by years and signals the FDA isn't confident the therapy is safe or effective enough yet.
→ The FDA will reject MDMA-assisted therapy approval in 2026 and request additional clinical evidence.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
FDA does not approve any MDMA-assisted therapy NDA in 2026, issuing a Complete Response Letter or requesting additional clinical data by December 31, 2026.. MAPS resubmission faces the same advisory committee precedent that generated a prior CRL. FDA's safety monitoring concerns around therapy protocol fidelity and abuse potential scoring remain unresolved. Four agents (fda_reviewer, dea_officer, investor, neuropharmacologist) support this; dissenting a
72%
DEA raids at least three ketamine clinics across different states
The DEA (the U.S. drug enforcement agency) will publicly announce at least three separate enforcement actions (raids, arrests, or clinic closures) against ketamine clinics in three different U.S. states before October 2026. Ketamine clinics operate in a legal gray zone—they prescribe ketamine (a legal but controlled anesthetic) for depression and pain, often via telemedicine. The DEA will likely target these clinics because the current political environment favors aggressive drug enforcement.
→ The DEA will raid or shut down at least three ketamine clinics across different states by October 2026.
Resolves: 2026-09-30 · USA
REGULATION
the precise call ▾
DEA executes publicly announced enforcement actions against at least three ketamine clinic operators in distinct U.S. states before October 1, 2026.. Ketamine clinics operating via telemedicine prescriptions represent the most legally accessible enforcement target: ketamine is Schedule III, clinics are operating in regulatory gray zones, and DEA has existing jurisdictional authority without needing Schedule I case construction. The current law-en
83%
Congress won't vote on psychedelic therapy bills before 2026 elections
No bill specifically creating legal pathways for psychedelic-assisted therapy will reach a floor vote (where all members vote) in the House or Senate before the November 2026 midterm elections. This matters because it means Congress won't formally debate or decide whether these therapies should be legal.
→ Congress won't hold a decisive floor vote on psychedelic therapy before the 2026 midterm elections.
Resolves: 2026-11-03 · USA
LEGISLATION
the precise call ▾
No federal psychedelic therapy legislation reaches a floor vote in either chamber of Congress before November 3, 2026 midterms.. Four independent agents (politician, dea_officer, fda_reviewer, journalist) converge on this outcome. Floor scheduling is controlled by leadership; the 2026 legislative calendar is dominated by law enforcement and public safety bills. Mental health caucus work remains committee-only. No credible whi
61%
Two more states legalize psilocybin therapy by end of 2026
At least two additional U.S. states will pass laws or ballot measures creating legal pathways for psilocybin-assisted therapy by November 30, 2026. Oregon and Colorado already did this. Other states like California, Washington, and Michigan have active ballot initiatives or legislative proposals. This matters because state-level action moves faster than federal action, so people in those states will get legal access even while the federal government hasn't approved it.
→ At least two more U.S. states will legalize psilocybin-assisted therapy by end of 2026.
Resolves: 2026-11-30 · USA
LEGISLATION
the precise call ▾
At least two additional U.S. states pass ballot measures or legislation creating regulated psilocybin therapy access frameworks by November 30, 2026.. Oregon (Measure 109) and Colorado (Prop 122) established precedent. Multiple states (including California, Washington, and Michigan) have active 2026 ballot initiatives or legislative tracks. State-level action is decoupled from federal hostility—indeed, federal inaction creates political space for